These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 21370008)
41. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955 [TBL] [Abstract][Full Text] [Related]
42. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920 [TBL] [Abstract][Full Text] [Related]
43. A fluorescence in situ hybridization (FISH) microfluidic platform for detection of HER2 amplification in cancer cells. Kao KJ; Tai CH; Chang WH; Yeh TS; Chen TC; Lee GB Biosens Bioelectron; 2015 Jul; 69():272-9. PubMed ID: 25770459 [TBL] [Abstract][Full Text] [Related]
44. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328 [TBL] [Abstract][Full Text] [Related]
45. Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Press OA; Guzman R; Cervantes M; Santiago A; Press MF Methods Mol Biol; 2014; 1180():181-207. PubMed ID: 25015148 [TBL] [Abstract][Full Text] [Related]
46. Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay. Viale G; Paterson J; Bloch M; Csathy G; Allen D; Dell'Orto P; Kjærsgaard G; Levy YY; Jørgensen JT Pathol Res Pract; 2016 Aug; 212(8):735-42. PubMed ID: 27461826 [TBL] [Abstract][Full Text] [Related]
48. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675 [TBL] [Abstract][Full Text] [Related]
49. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783 [TBL] [Abstract][Full Text] [Related]
50. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507 [TBL] [Abstract][Full Text] [Related]
51. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan. Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987 [TBL] [Abstract][Full Text] [Related]
52. Fixation time does not affect expression of HER2/neu: a pilot study. Ibarra JA; Rogers LW Am J Clin Pathol; 2010 Oct; 134(4):594-6. PubMed ID: 20855640 [TBL] [Abstract][Full Text] [Related]
53. General principles and methods for routine automated microRNA in situ hybridization and double labeling with immunohistochemistry. Singh U; Keirstead N; Wolujczyk A; Odin M; Albassam M; Garrido R Biotech Histochem; 2014 May; 89(4):259-66. PubMed ID: 24106971 [TBL] [Abstract][Full Text] [Related]
54. [Volume of 4% neutral buffered formaldehyde affects the results of Chen Z; Wang Y; Mi X; Duan L; Chen A; Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 46(4):439-444. PubMed ID: 29256235 [TBL] [Abstract][Full Text] [Related]
55. Simple technique of codenaturation and fluorescence in situ hybridization with probes in a microcamera. Bossi B; Comino A; Dalmasso M Cancer Genet Cytogenet; 2002 Dec; 139(2):133-7. PubMed ID: 12550773 [TBL] [Abstract][Full Text] [Related]
56. Telomere length measurements using fluorescence in situ hybridization and flow cytometry. Baerlocher GM; Lansdorp PM Methods Cell Biol; 2004; 75():719-50. PubMed ID: 15603450 [No Abstract] [Full Text] [Related]
57. TO-PRO-3 is an optimal fluorescent dye for nuclear counterstaining in dual-colour FISH on paraffin sections. Bink K; Walch A; Feuchtinger A; Eisenmann H; Hutzler P; Höfler H; Werner M Histochem Cell Biol; 2001 Apr; 115(4):293-9. PubMed ID: 11405057 [TBL] [Abstract][Full Text] [Related]
58. Reagent and labor cost optimization through automation of fluorescence in situ hybridization (FISH) with the VP 2000: an Italian case study. Zanatta L; Valori L; Cappelletto E; Pozzebon ME; Pavan E; Dei Tos AP; Merkle D J Lab Autom; 2015 Feb; 20(1):25-31. PubMed ID: 25395292 [TBL] [Abstract][Full Text] [Related]
59. A filtration, incubation and staining reactor including a new protocol for FISH. Poschen L; Klauth P; Groeneweg J; Wilhelm R J Microbiol Methods; 2002 Jun; 50(1):97-100. PubMed ID: 11943363 [TBL] [Abstract][Full Text] [Related]